A one-day point-prevalence survey (17 May 2022) at Muhimbili National Hospital's level III NICU (100 beds) screened 51 inborn neonates (mean gestational age 31.6 Β± 3.8 weeks; median age at sampling 8 days, IQR 11; 41% female) via rectal swabs, with ESBL confirmation by combination disk testing, WGS on Illumina NovaSeq 6000, and Optical DNA Mapping (ODM) of plasmids using Cas9 targeting of blaNDM-5 or blaCTX-M-15.
| Category | Organism | Count (n) |
|---|---|---|
| Screened neonates | All | 51 |
| EPE-colonized neonates | Any ESBL-producing Enterobacteriaceae | 31 (60.7%) |
| EPE isolates | ESBL-producing E. coli (EP-EC) | 19 |
| EPE isolates | ESBL-producing K. pneumoniae (EP-KP) | 21 |
| EPE isolates | ESBL-producing K. oxytoca (EP-KO) | 1 |
| Carbapenem-resistant isolates | K. pneumoniae | 10 |
| Carbapenem-resistant isolates | E. coli | 4 |
| Carbapenem-resistant isolates | K. oxytoca | 1 |
| Carbapenem-resistant isolates (total) | All species | 15 |
Note: isolate counts across species can exceed the 31 colonized neonates if a neonate carried more than one species; the paper does not report per-neonate co-carriage breakdowns (BGPT inference β flagging a known unknown).
| Gene | Carriage | Interpretation (author-reported) |
|---|---|---|
| blaNDM-5 | 15/15 (100%) | Universal in all carbapenem-resistant isolates |
| blaCTX-M-15 | 15/15 (100%) | Universal; not plasmid-borne in the investigated ODM plasmids |
| blaOXA-181 | 8/15 (53%) | Present in subset, co-carried with NDM-5 and CTX-M-15 |
Clonal types detected: K. pneumoniae ST437 (CC11), ST392, ST147; E. coli ST167; K. oxytoca carried blaNDM-5/blaCTX-M-15 with one KO isolate unassigned for ST.
| Parameter | Detail |
|---|---|
| Isolates analyzed | 4 K. pneumoniae ST437 + 2 E. coli ST167 |
| Plasmid sizes | 58β211 kb |
| Mean plasmid size | ~151.4 kb |
| blaNDM-5 location | Plasmid-borne in all 6 analyzed plasmids |
| blaCTX-M-15 location | Not plasmid-borne in investigated plasmids |
| Plasmid similarity | Highly similar (P < 0.001), suggesting plasmid transfer across species |
| Method | ODM with Cas9 targeting blaNDM-5/blaCTX-M-15; MATLAB analysis; YOYO-1/netropsin staining |
E. coli (n=19): piperacillin-tazobactam 47%, meropenem 31%, ertapenem 31%, imipenem 26%, amikacin 26%, gentamicin 47%, trimethoprim-sulfamethoxazole 84%, ciprofloxacin 63%. K. pneumoniae (n=21): PTZ 62%, MEM 38%, ETP 43%, IMI 43%, amikacin 24%, gentamicin 57%, SXT 95%, ciprofloxacin 71%. These values correspond to the bar chart above; the paper reports only these percentages without confidence intervals.
Limitations: single-site, single-day design; n=51; descriptive only with no risk-factor analysis; incomplete AWaRe data; ODM restricted to a 6-plasmid subset; cot-sharing incompletely captured β all stated by the authors. Confidence in the tabulated values is high (direct extraction), but generalizability beyond this NICU is limited by design.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.